menu
    • menu
    [{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breath Therapeutics, a Zambon Company, Initiates BOSTON-3 and BOSTON-4, Two Additional Clinical Studies for the Treatment of Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A new FDA Fast Track designation for Zambon","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson\u2019s Disease Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zambon Switzerland","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Zambon Swi.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb\u00ae in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Ab-Biotics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19. A Probiotic Formula Reduces Symptom Duration and Viral Load, Increases Antibodies, and Improves Remission Rate Among Patients With Mild Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KABP022","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zambon Group SpA \/ Zambon","highestDevelopmentStatusID":"1","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Phase 3 PROMIS-I Study of CMS I-neb\u00ae in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Pari","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Cyclosporine A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Pari","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Zambon Exclusive Commercialization Rights to its Innovative Alzheimer\u2019s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Zambon Group SpA \/ Zambon Group Spa","highestDevelopmentStatusID":"12","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Carbidopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zambon Group SpA \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."}]

    Find Clinical Drug Pipeline Developments & Deals by Zambon Group SpA

    Menu

    Zambon Group SpA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carbidopa,Etilevodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

                            Details : Through the licensing agreement, Zambon will commercialize IPX203, an oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson’s disease.

                            Product Name : IPX203

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 27, 2024

                            Lead Product(s) : Carbidopa,Etilevodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Amneal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liposomal Cyclosporine A

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Pari

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclospor...

                            Details : L-CsA-i (Liposomal Cyclosporine A) is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH) for the treatment of BOS in adults foll...

                            Product Name : L-CsA

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 01, 2023

                            Lead Product(s) : Liposomal Cyclosporine A

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Pari

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Newron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia

                            Details : Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.

                            Product Name : Xadago

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 15, 2023

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Newron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting

                            Details : Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin. Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.

                            Product Name : Promixin

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 12, 2022

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cys...

                            Details : Promixin (Colistimethate Sodium) is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic,...

                            Product Name : Promixin

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            April 21, 2022

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KABP022,KABP023,KABP033

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Ab-Biotics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Covid-19. A Probiotic Formula Reduces Symptom Duration and Viral Load, Increases Antibodies, and I...

                            Details : AB21 (KABP022) formula, consisting of four specific probiotic strains, produces significant positive effects in COVID-19 outpatients, with benefits on remission rate, symptom duration and viral load.

                            Product Name : AB21

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 21, 2022

                            Lead Product(s) : KABP022,KABP023,KABP033

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Ab-Biotics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Luye Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Luye Pharma Grants Zambon Exclusive Commercialization Rights to its Innovative Alzheimer’s Disea...

                            Details : Through the agreement, the company grants Zambon exclusive rights to commercialize Rivalif (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

                            Product Name : Rivalif

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 10, 2021

                            Lead Product(s) : Rivastigmine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Luye Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis B...

                            Details : Data shows inhalation via the I-neb ® Adaptive Aerosol Delivery System of Promixin (colistimethate sodium) results in reduction of pulmonary exacerbations in non-cystic fibrosis bronchiectasis (NCFB) pat...

                            Product Name : Promixin

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            September 08, 2021

                            Lead Product(s) : Colistimethate Sodium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Zambon Switzerland

                            Switzerland arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Switzerland

                            Switzerland arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Newron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Di...

                            Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will ...

                            Product Name : Xadago

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 12, 2021

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Newron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Zambon Group SpA

                            Italy arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            A new FDA Fast Track designation for Zambon

                            Details : FDA has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            April 28, 2020

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth